Leukemia Clinical Trials
Phase I Agents for Hematologic Malignancies
- Hu8F4 (2014-0057)
- ONC20 (2014-0731)
- SL-401(2014-0976)
- K0706 (2016-0648)
- Palbociclib (2016-0772)
- AMG 176 (2017-0776)
- IMGN632 (2017-0855)
- UCART22 (2017-1003)
- AMG427 (2018-0596)
- LOXO-305 (2018-0850)
- CPX-351 (2018-0911)
- HM43239 (2018-0918)
- S64315 + Venetoclax (2018-1007)
- PBCAR0191 (2019-0218)
- CPX-351 + Quizartinib (2019-0351)
- Azacitidine + Venetoclax + Gilteritinib (2019-0366)
- Venetoclax + Aza (2019-0368)
- IMG632 + Venetoclax +/- Azacitidine (2019-0656)
- HQP1351 (2019-0705)
- Voruciclib (2019-0738)
- SNDX-5613 (2019-0997)
- LP-108 (2019-1089)
- TAS1440 or TAS1440 + ATRA (2019-1231)
- CA-4948 (2019-1246)
- Oral Azacitidine + ASTX030 vs. SQ Azacitidine (2020-0025)
- Azacitidine + Venetoclax + Magrolimab (2020-0027)
- Venetoclax + ASTX727 (2020-0129)
- Blinatumomab (2020-0133)
- NKX101 (2020-0227)
- CB-5339 (2020-0302)
- INCB000928 +/- Ruxolitinib (2020-0409)
- APG-115 + Azacitidine (2020-0422)
- Fludarabine + Ara-C + Pegcrisantaspase (2020-0434)
- IO-202-CL-001 (2020-0492)
- Tegavivint (BC-2059) (2020-0616)
- GFH009 (2020-0689)
- Omacetaxine + Venetoclax (2020-0890)
- Tagraxofusp + Decitabine (2020-0895)
- CG-806 (2020-0900)
- BGB-11417 (2020-0956)
- Fostamatinib (2020-1117)
- NX-2127 (2020-1169)
- HMPL-306 (2020-1321)
- KITE-222 (2021-0007)
- AZD0466 (2021-0032)
- CC-96191 (2021-0047)
- ASTX727 + Venetoclax + Gilteritinib (2021-0082)
- CC-91633 (2021-0154)
- VOB560 +/- Azacitidine (2021-0220)
- REGN7257 (2021-0245)
- AMG176 +/-Azacitidine (2021-0276)
- Venetoclax + ADI PEG20 + Azacitidine (2021-0285)
- MK-0482 (2021-0301)
- JNJ-7526617 (2021-0319)
- SY-2101 (2021-0407)
- FT538 (2021-0414)
- mini-HCVD + SL-401 (2021-0545)
- APG-2575 + Azacitidine (2021-0566)
- CC-486 + Venetoclax (2021-0590)
- CLN-049 (2021-0593)
- DSP107 (2021-0654)
- DSP-5336 (2021-0711)
- CYNK 001 +/- rhIL-2 (2021-0718)
- CYC065 (2021-0771)
- RO728342 (2021-0808)
- SAR443579 (2021-0877)
- Iadademstat + Gilteritinib (2021-0966)
- CC-95251 +/- Azacitidine (2021-1046)
- BTX-1188 (2021-1056)
- BGB-11417 (2021-1058)
- SNDX-5613 (2021-1059)
- SNDX-5613 (2021-1107)
- Siremadlin + Venetoclax + Azacitidine (2021-1181)
- Gilteritinib + Venetoclax + Azacitidine (2022-0036)
- SL-1752154 + Azacitidine or Azacitidine + Venetoclax (2022-0038)
- PRT1419 (2022-0075)
- LP-118 (2022-0249)
- DISC-0947 (2022-0291)
- LAVA-051 (2022-0424)
- JNJ-72576617 (2022-0427)
- IGM-8444 (2022-0542)
- SPRX002 (2022-0817)
- NC525 (2022-0952)
Monoclonal
CD33
- CC-96191 (2021-0047)
CD123
- SL-401(2014-0976)
- SL401 + Azacitidine (2017-0354)
- IMGN632 (2017-0855)
- IMG632 + Venetoclax +/-Azacitidine (2019-0656)
CD22
HLA
- HU8F4 (2014-0057)
LILRB4
- IO-202 (2020-0492)
TP53 Directed Therapy
- AZA + Venetoclax + Magrolimab (2020-0027)
- TTI-662 + Azacitidine +/- Venetoclax (2018-1064)
- LX148 + Venetoclax + Azacitidine (2021-0144)
- DSP107 (2021-0654)
- SL-1752154 + Azacitidine or Azacitidine + Venetoclax (2022-0038)
IDH Inhibitors
- HMPL-306 (2020-1321)
- AG120 (2017-0490)
- AG120 (2014-0800)
- CPX-351 + Ivosidenib (2020-0096)
- Enasidenib + Azacitidine (2018-0499)
- LY3410738 (2020-0676)
- Ivosidenib or Enasidenib (2020-1220)
CAR-T Studies
B-ALL
- U-CART22 in R/R CD22+ B-ALL (2017-1003)
- PBCAR0191 (CAR-T) in R/R B-Cell ALL (2019-0218)
- AUTO1-AL1 (2020-0435)
- Fate FT819 (2020-0775)
CLL
AML
Other Cellular AML
Menin Inhibitors
Acute Lymphoblastic Leukemia (ALL)
Newly Diagnosed or Previously Treated
- Hyper CVAD + Blinatumomab (2014-0845)
- mHCVD + Inotuzumab +/-Blinatumomab (2010-0991)
- Hyper-CVAD + Nelarabine (2006-0328)
- Low-Intensity Chemo + Venetoclax (2016-0629)
- Hyper-CVAD + Ponatinib (2011-0030)
- Blinatumomab + Ponatinib (2016-0792)
- Hyper CVD + Ponatinib (2016-0402)
Minimal Residual Disease
- Inotuzumab (2015-0921)
Salvage Programs
- Blinatumomab (2020-0133)
- Low-Intensity Chemo + Venetoclax (2016-0629)
- AUTO1-AL1 (2020-0435)
- ADCT-602 (2017-0938)
- UCART22 (2017-1003)
- SAR443579 (2021-0877)
- iC9/CAR (2016-0641)
- CEC + VCR + Bortezomib (2016-0211)
- Blinatumomab + Ponatinib (2016-0792)
- Hyper CVD + Ponatinib (2016-0402)
- Ponatinib + mini-HCVD + Venetoclax (2021-0802)
- Hyper-CVAD + Nelarabine (2006-0328)
- Palbociclib (2016-0772)
- SNDX-5613 (2019-0997)
- JNJ-7526617 Menin Inhibitor (2021-0319)
Phase I/II Open to ALL
Acute Myeloid Leukemia (AML)
Newly Diagnosed
- Fludarabine + Ara-C + G-CSF + Gemtuzumab (2007-0147)
- ATRA and arsenic +/- Gemtuzumab (2010-0981)
- SY-2101 (2021-0407)
- Cladribine + Ida + Ara-C (2012-0648)
- FLAG-Ida + Venetoclax (2016-0979)
- CPX-351 + Venetoclax (2017-1055)
- CLIA + Quizartinib (2017-0153)
- Venetoclax + Daunorubicin/Ara-C (2019-0591)
- BP1001 + LD Ara-C (2016-0128)
- Venetoclax + Cladribine + LDAC + LDAC w/ Azacitidine (2018-0020)
- Dexrazoxane (2017-0937)
- Cladribine + LD Ara-C alternating DAC (2011-0987)
- Venetoclax + ASTX727 (2020-1007)
- CART123 (2017-0559)
- SL401 + Azacitidine (2017-0354)
- Azacitidine + Magrolimab (2021-0186)
- ALX148 + Venetoclax + Azacitidine (2021-0144)
- AZA + Venetoclax + Magrolimab (2020-0027)
- Magrolimab/Placebo + Venetoclax + Azacitidine (2021-0790)
- SY-1425 + Venetoclax + Azacitidine (2021-0230)
- Venetoclax + Decitabine (2017-0912)
- TTI-662 + Azacitidine +/- Venetoclax (2018-1064)
- APG-2575 + Azacitidine (2021-0566)
- SL-1752154 + Azacitidine or Azacitidine + Venetoclax (2022-0038)
- BST-236 + Venetoclax (2022-0509)
- Nivolumab + Azacitidine (2014-0861)
TP35 Mutated Only
FLT3 Mutated Only
- CLIA + Quizartinib (2017-0153)
- Azacitidine + Venetoclax + Gilteritinib (2019-0366)
- Quinzartinib + DAC (2018-0394)
- Quizaritinib + Azacitidine (2019-1178)
- CPX-351 + Quizartinib (2019-0351)
- Gilteritinib + Venetoclax + Azacitidine (2022-0036)
IDH Mutated only
- AG120 (2017-0490)
- CPX-351 + Ivosidenib (2020-0096)
- LY3410738 (2020-0676)
- Enasidenib + AZA (2018-0499)
- Ivosidenib or Enasidenib (2020-1220)
RUNX1 mutated AML
- Omacetaxine + Venetoclax (2020-0890)
- SEL 120 (2019-0263)
- CYC065 (2021-0771)
- SNDX-5613 (2021-1107)
- Voruciclib (2019-0738)
- GFH009 (2020-0689)
Frontline AML Post-Hypomethylating Therapy for MDS
- Uproleselan + Cladribine + Low-Dose Cytarabine (2020-0988)
- Venetoclax + ASTX727 (2020-1007)
- BP1001 + LD Ara-C (2016-0128)
Secondary Leukemia
- Uproleselan + Cladribine + Low-Dose Cytarabine (2020-0988)
- Venetoclax + ASTX727 (2020-1007)
- Cladribine + LD Ara-C alternating DAC (2011-0987)
Mixed Phenotype Acute Leukemia
- Fludarabine + Ara-C + Pegristantaspase (2020-0434)
- SNDX-5613 (2019-0997)
- JNJ-7526617 (2021-0319)
- APG-2575 + Azacitidine (2021-0566)
- DSP-5336 (2021-0711)
Salvage
FLT3 Positive at relapse
- ASTX727 + Venetoclax + Gilteritinib (2021-0082)
- CLIA + Quizartinib (2017-0153)
- Cladribine + Ida + Ara-C + Sorafenib (2012-0648)
- AZA + Venetoclax + Gilteritinib (2019-0366)
- Quinzartinib + DAC (2018-0394)
- HM43239 (2018-0918)
- Palbociclib (2016-0772)
- ASTX727-10 + Venetoclax (2021-0248)
- Venetoclax + Decitabine (2017-0912)
- CPX-351 + Quizartinib (2019-0351)
- NKX101 (2020-0227)
- Iadademstat + Gilteritinib (2021-0966)
RAS Mutated
AML with MLL gene at 11q23 Translocations
- SNDX-5613 (2019-0997)
- KO-539 (2020-0717)
- DS-1594 +/- AZA + Venetoclax or mini HCVD (2020-0946)
- NJ-7526617 Menin Inhibitor (2021-0319)
- SNDX-5613 (2021-1107)
- SNDX-5613 (2021-1059)
- SNDX-5613 +/- Chemo (2022-0067)
AML with mutation in NPM1
- SNDX-5613 (2019-0997)
- KO-539 (2020-0717)
- NJ-7526617 Menin Inhibitor (2021-0319)
- SNDX-5613 (2021-1107)
- SNDX-5613 +/- Chemo (2022-0067)
IDH Mutated
- HMPL-306 (2020-1321)
- LY3410738 (2020-0676)
- AG120 (2017-0490)
- Enasidenib + AZA (2018-0499)
- Venetoclax + Decitabine (2017-0912)
- NKX101 (2020-0227)
- Ivosidenib or Enasidenib (2020-1220)
All others (Regardless of mutation status)
- KO-539 (2020-0717)
- NKX101 (2020-0227)
- CC-486 + Venetoclax (2021-0590)
- S64315 + Venetoclax (2018-1007)
- ZN-d5 + ZN-c3 (2022-0595)
- CPX-351 + Venetoclax (2017-1055)
- FLAG-Ida + Venetoclax (2016-0979)
- Pilot Study CPX-351 w/ Gemtuzumab (2018-0235)
- Venetoclax + ASTX727 (2020-1007)
- Cladribine + Ida + Ara-C + Sorafenib (2012-0648)
- Nivolumab + 5-AZA (2014-0861)
- Venetoclax + Decitabine (2017-0912)
- CART123 (2017-0559)
- SL401 + AZA (2017-0354)
- Fludarabine + Ara-C + Pegristantaspase (2020-0434)
- FT516 (2019-0615)
- Siremadlin + Venetoclax + Azacitidine (2021-1181)
- Voruciclib (2019-0738)
- SL-1752154 + Azacitidine or Azacitidine + Venetoclax (2022-0038)
- Cladribine + Ida + Ara-C + Sorafenib (2012-0648)
- DFP-10917 vs Non-Intensive Reinduction (2019-0357)
- CA-4948 (2019-1246)
- GFH009 (2020-0689)
- Tegavivint (BC-2059) (2020-0616)
- DSP107 (2021-0654)
- AMG 176 (2017-0776)
- RO728342 (2021-0808)
- VOB560 +/- Azacitidine (2021-0220)
- CC-95251 +/- Azacitidine (2021-1046)
- BP1002 (2021-1018)
- CFI-400945 +/- Azacitidine or Decitabine (2020-1061)
AML with Monocytic Differentiation
Maintenance (Patients in CR)
- Oral Azacitidine + Venetoclax (2021-0303)
- AZA + Venetoclax (2019-0226)
- Galinpepimut-S (2020-0252)
- IMG632 + Venetoclax +/- Azacitidine (2019-0656)
BPDCN Treatment Priorities
- SL-401 + HCVAD or mHCVAD + Venetoclax (2019-0587)
- IMGN632 (2017-0855)
- Venetoclax + Decitabine (2017-0912)
- MB CAR-T (2019-0097)
Myelodysplastic Syndrome (MDS) (Includes CMML)
MDS/MPN
FLT3 Positive
- Quinzartinib + DAC (2018-0394)
- Quizaritinib + AZA (2019-1178)
- CPX-351 + Quizartinib (2019-0351)
- AZA + Venetoclax + Gilteritinib (2019-0366)
IDH Mutations
- CPX-351 + Ivosidenib (2020-0096)
- AG120 (2017-0490)
- HMPL-306 (2020-1321)
- AG120 (2014-0800)
- LY3410738 (2020-0676)
- AG221 (2016-0981)
RUNX1 Mutations
- Omacetaxine + Venetoclax (2020-0890)
Low Risk/IPSS Int-1
- Azacitidine + BSC vs Placebo + BSC (2022-0701)
- Fostamatinib (2020-1117)
- AZA + Cedazuridine (ASTX030) vs. SQ AZA (2020-0025)
- H3B-8800 (2022-0247)
- R289 (2022-0186)
IPSS int-2 or high
- ALX148 + AZA (2020-0572)
- Venetoclax + ASTX727 (2020-0129)
- enetoclax + AZA (2019-0368)
- Cladribine + LD Ara-C alt DAC (2011-0987)
- Cladribine + Ida + Ara-C + Sorafenib (2012-0648)
- FLAG-Ida + Venetoclax (2016-0979)
- Venetoclax + Decitabine (2017-0912)
- KPT-8602 (2021-0497)
- Magrolimab/Placebo + AZA (2020-0546)
- MBG453 + Azacitidine + Venetoclax (2021-0601)
- AZA + Cedazuridine (ASTX030) vs. SQ AZA (2020-0025)
- Cladribine + Venetoclax (2021-1116)
Post Hypomethylating Agents
- Oral AZA + ASTX030 vs. SQ AZA (2020-0025)
- Fostamatinib (2020-1117)
- Canakinumab (2019-0339)
- SL-401(2014-0976)
- INCB000928 (2020-0983)
- NIS793 + MBG453 + Canakinumab (2020-0183)
- Tagraxofusp + Decitabine (2020-0895)
- Seclidemstat + AZA (2020-0487)
- AMG176 +/-Azacitidine (2021-0276)
- R289 (2022-0186)
- CA-4948 (2019-1246)
- Venetoclax + AZA (2020-0128)
- CPX-351 (2018-0911)
- Ven + AZA (2019-0368)
- FLAG-Ida + Venetoclax (2016-0979)
- Venetoclax + Decitabine (2017-0912)
- Pilot Study CPX-351 w/ Gemtuzumab (2018-0235)
- KPT-8602 (2021-0497)
- SAR443579 (2021-0877)
- Vibecotamab (2021-1124)
- NKX101 (2020-0227)
- CB-5339 (2020-0302)
- Cladribine + Venetoclax (2021-1116)
Chronic Lymphocytic Leukemia (CLL)
CLL Immunotherapy
Untreated - early stage
Untreated - all stages
- Pirtobrutinib + Venetoclax + OBIN (2021-0578)
- Atezolizumab (2015-1097)
- Zanubrutinib + Rituximab (2019-0012)
- Acalabrutinib + Obinutuzumab (2019-1141)
Consolidation and Minimal Residual Disase (MRD)
Prior Therapy
- LP-118 (2022-0249)
- Mosunetuzumab (2022-0055)
- BGB-11417 (2020-0956)
- Ipilimumab + Ibrutinib + Nivolumab (2020-0571)
- CYC065 (2021-0771)
- BMF-219 (2021-0815)
- MS-553 (2021-0272)
- Acalabrutinib + Ven + Obinutuzumab (2019-0565)
- LOXO-305 + Venetoclax + Rituximab vs Venetoclax + Rituximab (2021-0504)
- FT819 (2020-0775)
- NX-2127 (2020-1169)
Richter’s Transformation
- Pirtobrutinib + Venetoclax + OBIN (2021-0578)
- Atezolizumab (2015-1097)
- Ipilimumab + Ibrutinib + Nivolumab (2020-0571)
- LP-118 (2022-0249)
- EPOCH-R + Venetoclax (2016-0900)
- MS-553 (2021-0272)
- Fate FT819 (2020-0775)
Other Studies
- 2CDA + Rituximab in Hairy Cell Leukemia (2004-0223)
T-Cell Prolymphocytic Leukemia (T-PLL)
- APG-115 +/- APG-2575 (2020-1155)
Chronic Myelogenous Leukemia (CML)
Chronic phase
- Dasatinib + ASTX727 (2021-0271)
- Asciminib (2021-0828)
- Asciminib (2020-1135)
- ABL001 + TKI (2019-0618)
- Ponatinib (2012-0669)
- HQP1351 (2019-0705)
- K0706 (2016-0648)
Accelerated Phase
Blastic Phase
Imatinib failures with T315l mutations (any stage)
Minimal Residual Disease
Myeloproliferative Neoplasms (MPN)
- CPI-0610/Placebo + Ruxilitinib (2020-0739)
- TL-895 + Ruxolitinib (2022-0183)
- Ruxolitinib + AZA (2012-0737)
- KRT-232 + Ruxolitinib (2020-0279)
- INCB057643 + Ruxolitinib (2021-1092)
- CK0804 TREG Study (2021-0341)
- Imetelstat vs BAT (2020-1141)
- GB2064 (2020-1217)
- KRT-232 (2018-0906)
- PXS-5505 (2021-0753)
- Luspatercept/Placebo (2020-1010)
- INCB000928 +/- Ruxolitinib (2020-0409)
- Elotuzumab (2020-0522)
- DISC-0947 (2022-0291)
- NS-018 vs BAT (2021-0348)
- TL-895 (2020-0738)
- ISIS 702843 for phlebotomy-dependent (2021-0897)
- PTG-300/Placebo (2022-0005)
- Ropeginterferon alfa-2b (P1101) (2020-0108)
- CGT9486 (2021-0587)
- CGT9846 (2021-0880)
- BLU-263 (2022-0072)
Give Now
Your gift will help make a tremendous difference.
Research Areas
Find out about the four types of research taking place at MD Anderson.
Subscribe
Get the latest information on our cancer breakthroughs.